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R177With this motivation, the groups of 
Michael Groll at the Technical University 
of Munich and of Marcus Groettrup at 
the University of Konstanz have recently 
solved the crystal structures of both the  
constitutive proteasome and the 
immunoproteasome of mice, each with 
and without the epoxyketone PR957, 
which is the only selective inhibitor 
of b5i known so far. In addition, the 
researchers also solved the structure of 
the yeast proteasome with and without 
this inhibitor (Cell (2012), 148, 727–738). 
The detailed analysis of these 
structures revealed the molecular 
basis for the specificity of the inhibitor, 
which turned out to be extremely 
subtle. The researchers found that 
a single methionine residue in the 
immunoproteasome adopts a different 
conformation than in the constitutive 
proteasome due to small structural 
differences in its surroundings. “This 
distinct conformation is crucial,” 
explains the first author of the paper, Eva 
Maria Huber. “It results in a larger pocket 
in the immunoproteasome, which 
therefore preferentially accommodates 
bulky amino acids and also the inhibitor. 
In contrast, constitutive proteasomes 
harbor a significantly smaller cavity that 
hampers binding of PR-957.”
What does all this mean for disease 
and drug development? “How the 
immunoproteasome is mechanistically 
involved in the pathogenesis of 
autoimmune diseases is still elusive,” 
says Marcus Groettrup. “The 
proteasome can perform site-specific 
cleavages within proteins and release 
a processed, biologically active 
polypeptide. We hypothesize that the 
immunoproteasome may selectively 
process or degrade a factor which is 
required for proinflammatory immune 
responses in autoimmunity.”
As yet, only one approved 
pharmaceutical agent, the cancer drug 
bortezomib, targets the proteasome, but 
the authors hope that, on the basis of the 
detailed structural knowledge they have 
provided for the whole range of different 
subunits in the constitutive proteasome 
and in the immunoproteasome, more 
specific drugs can be developed 
to target specific functions of the 
proteasome. Thus, understanding  
the complexities of oligomeric  
proteins will also become very useful 
knowledge. 
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Pieter Roelfsema studied medicine 
in Groningen, Netherlands between 
1983 and 1991. He worked for his 
PhD degree in Frankfurt, Germany 
between 1991 and 1995 in the lab 
of Wolf Singer, where he studied the 
role of neuronal synchrony in feature 
binding. He received his PhD from 
the University of Amsterdam in 1995 
and came back to the Netherlands to 
do a post-doc studying the neuronal 
mechanisms for perceptual grouping 
in the primate visual system. Since 
2007 he has been the director 
of the Netherlands Institute for 
Neuroscience (KNAW) in Amsterdam 
and he is also strategic professor at 
the VU University in Amsterdam. If 
asked what summarizes his approach 
to science he says ‘usually too 
ambitious but sometimes it comes 
together’.
Why did you go into neuroscience? 
At high school I was first attracted to 
the physical sciences. But I changed 
my mind because a life surrounded 
by people seemed more interesting 
than one surrounded by test tubes. 
So I decided to study medicine so 
that I could learn about the science 
with the prospect of helping patients. 
The first two years of study, which I 
did in Groningen, in the north of the 
Netherlands, were very interesting. 
From the third year on we learned 
the mappings between symptoms 
and diseases. I vividly remember 
my father giving me the book 
‘Gödel Escher Bach’ by Douglas 
Hofstadter. It completely changed my 
perspective. From then on I wanted 
to know what consciousness is, how 
we think and remember. I started 
to read textbooks on neuroscience 
and then papers. I was fascinated 
by papers I read on learning and 
plasticity by Yves Fregnac, Mark Bear 
and Wolf Singer and I interrupted my 
medical training to do a student’s 
project on the neurophysiology of 
snails and then one on learning in 
rats. I learned a lot in this period, but 
also came to realize that doing good 
research is team work. As a novice 
it seemed to be a good idea to go to 
a top-level lab. Fernando Lopes da 
Silva helped me by sending a letter 
Q & A of recommendation to Wolf Singer at the Max-Planck-Institute in Frankfurt. 
When I went to Frankfurt for an 
interview, Singer told me that I should 
first finish training for my MD degree, 
but that I would be welcome in his 
lab afterwards. So I went back to 
Groningen for two years and finished 
my clinical training. I was relieved to 
find out that Singer’s offer to join his 
lab was still valid after these years.
Why did you choose to study 
‘binding’ in visual perception? It was 
not my own choice. I was attracted to 
Wolf Singer’s lab to study plasticity, 
but the binding problem — how the 
brain binds together information 
about the various features of a 
particular object which may be 
processed in separate areas — and 
the role of oscillatory synchrony 
had become the major research 
topic in his lab when I arrived. The 
scientific climate in the Singer lab 
was fantastic, with Andreas Engel, 
Peter König, and later Pascal Fries 
and many others present. People 
were excited about the binding 
problem and we all felt that we were 
in the middle of a great discovery. For 
my first project, I recorded from the 
visual cortex of cats with amblyopia. 
I was thrilled to record from single 
neurons that we stimulated with a 
bar of light using a hand-held lamp, 
very much as Hubel and Wiesel had 
done. In my project, we found that 
cortical neurons connected to the 
amblyopic eye did not synchronize 
as well as those connected to the 
normal eye, supporting the idea of 
a functional role of synchrony in 
cortical processing. Later projects 
focused on the interactions between 
brain areas where we also observed 
synchronization. We did realize, 
however, that one crucial piece of 
evidence for binding-by-synchrony 
was lacking: no one had shown that 
the patterns of synchrony in the 
visual cortex were correlated with 
binding in perception. 
What has been your biggest 
research mistake? I am not sure 
that I would call it a mistake, but the 
concept of binding-by-synchrony 
turned out to be wrong. When I 
went back to Amsterdam in 1995 
to work with Henk Spekreijse and 
Victor Lamme, I was determined to 
show once and for all that synchrony 
was responsible for binding in 
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tracing task where monkeys had to 
determine the end-point of a curvy 
line, with the idea that this task 
required perceptual grouping of 
all line elements. Soon I recorded 
my first data, and they did not 
support binding-by-synchrony at 
all. I had written papers about the 
importance of synchrony for binding 
and the negative findings made 
me worry that my career might be 
ending. Fortunately, we found that 
neurons that responded to the 
line elements that were bound in 
perception fired more spikes than 
neurons that responded to irrelevant 
line elements. Although I briefly 
thought that I had encountered 
another problem, because firing-rate 
differences complicate the analysis 
of synchrony, I soon realized that 
we were looking at the neuronal 
correlates of object-based attention. 
We later showed that, in other 
cases, object-based attention also 
works by labeling a subset of image 
elements with enhanced neuronal 
activity. We are now coming to 
an understanding of binding at a 
mechanistic, psychological and 
also neurophysiological level, as an 
interaction between areas in visual 
and frontal cortex. As a general 
lesson one might conclude: it does 
not matter if your theory is wrong as 
long as you ask the right question 
and do the right experiment. 
Who are your scientific heroes? I 
admire Wolf Singer for his attitude 
towards science; he has been a role 
model for me. I am also a fan of 
Shimon Ullman, who is a very original 
thinker and predicted many insights 
into visual processing in the 1980s 
that impacted on my work. Then 
there is Marvin Minsky. I was very 
inspired by his books (written with 
Seymour Papert) about perceptrons 
(a type of model neural network), 
Turing machines and consciousness. 
I was really impressed to learn that 
he is also the inventor of the confocal 
microscope. 
What is your favorite subject? 
Minsky wrote that a real 
understanding of brains requires us 
to understand how the mind is built 
from ‘mindless stuff’. Ever since 
reading Gödel Escher Bach it has 
been my ambition to understand how 
thoughts emerge from matter. The curve-tracing task helps, because 
we see a very nice correspondence 
between neurophysiology, where the 
enhanced neuronal activity spreads 
along a curve, and psychology, where 
subjects gradually spread object-
based attention along a curve. I like 
to call this ‘thinking along a curve’, 
although others might say that this is 
not what they call ‘thinking’. 
The other topic that I have always 
been very excited about is learning 
and plasticity. How does the brain 
reconfigure itself by feedback from 
the environment? As a medical 
student I was inspired by the book on 
‘Parallel Distributed Processing’ by 
Rumelhard and McClelland. Reading 
this book, I thought it should be 
possible to train a neuronal network 
with Hebbian plasticity switched 
on whenever a reward is given. 
Back then, I never got my simulated 
networks to learn anything useful. 
This changed when I read Sutton and 
Barto’s 1998 book on ‘Reinforcement 
Learning’. This book reviewed many 
of the insights from the reinforcement 
literature, and pointed out that the 
important signal is not the reward 
itself, but rather the deviations from 
the reward expectancy. When this 
insight is combined with what we 
know about the neurophysiology of 
attentional signals, very powerful 
but biologically plausible learning 
rules can be construed. The beautiful 
findings of Wolfram Schultz that 
dopamine cells code precisely such a 
signal amazed me. I believe that very 
many important insights into learning 
will be obtained in the coming 
years, given the powerful imaging 
techniques we have nowadays, 
the new ways to control activity, 
for example, using optogenetics, 
and methods for controlling the 
biochemistry of neurons.
What would be your advice to 
someone starting a career in 
biology? First of all, be very selective 
with the lab that you choose for 
your PhD project and your first 
postdoc. Initially concentrate on the 
techniques and on the questions this 
lab is good at. Read a lot, especially 
about the connection between what 
you do and the things you might want 
to focus on later so you can start 
forming your own mature ideas. After 
having completed one or two studies, 
start asking your own questions 
and bend the research in your own direction. And enjoy your time and 
the freedom of being in science! We 
are privileged to work on the things 
that really interest us. 
Do you have a publication strategy? 
I always tried to publish some of 
my papers in journals with a high 
visibility. As a result, they got 
rejected very often. But as scientists 
we have a responsibility not only to 
do good research, but also to make 
sure that it is read, and having a 
few high impact papers makes a 
big difference, if only in obtaining 
funding for your work. At our 
institute, we recently discussed the 
best possible publication strategy 
with our PhD students. We came 
to the conclusion that, for the 
PhD students who want to stay in 
science, it would also be a good 
idea to first aim high, because it then 
becomes easier to get one of the 
personalized grants that are available 
for young researchers. I am very glad 
that there are now many of these 
grants available, because they help 
young researchers to develop their 
own research. Of course, there is a 
degree of luck in making discoveries 
so there is no fool-proof way to do it. 
Do you think about the impact 
of your work for society? To be 
honest, I usually chose projects 
that seemed most interesting from 
a scientific point of view. But being 
trained as medical doctor, I think 
it would be great to bring new 
knowledge into the clinic. Some of 
the fundamental insights are finding 
their way there — for example, I have 
great expectations for deep-brain 
stimulation, which has been used to 
treat Parkinson’s disease for many 
years, but there are many emerging 
applications in psychiatry. I also 
believe that neuroscience will help to 
design a new generation of robots. 
Scientists are designing new flexible 
robots, which will perceive and act in 
the world like animals and knowledge 
about brains will make the difference 
in designing their control systems.
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